JP2008518007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518007A5 JP2008518007A5 JP2007538989A JP2007538989A JP2008518007A5 JP 2008518007 A5 JP2008518007 A5 JP 2008518007A5 JP 2007538989 A JP2007538989 A JP 2007538989A JP 2007538989 A JP2007538989 A JP 2007538989A JP 2008518007 A5 JP2008518007 A5 JP 2008518007A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- capreomycin
- aggregate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims 6
- 108010065839 Capreomycin Proteins 0.000 claims 6
- 229960004602 capreomycin Drugs 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- -1 rifapicin Chemical compound 0.000 claims 3
- 201000008827 tuberculosis Diseases 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960003376 levofloxacin Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- AHJGUEMIZPMAMR-WZTVWXICSA-N 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F AHJGUEMIZPMAMR-WZTVWXICSA-N 0.000 claims 1
- LEILBPMISZFZQK-GFCCVEGCSA-N 5-amino-7-[(7s)-7-azaniumyl-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylate Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3C3CC3)=O)C(N)=C1F)C)CC2 LEILBPMISZFZQK-GFCCVEGCSA-N 0.000 claims 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010027249 Meningitis meningococcal Diseases 0.000 claims 1
- 201000010924 Meningococcal meningitis Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 229950006412 delafloxacin Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002599 rifapentine Drugs 0.000 claims 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 229960003177 sitafloxacin Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62373804P | 2004-10-29 | 2004-10-29 | |
| PCT/US2005/037484 WO2007011396A2 (en) | 2004-10-29 | 2005-10-19 | Particles for treatment of pulmonary infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518007A JP2008518007A (ja) | 2008-05-29 |
| JP2008518007A5 true JP2008518007A5 (enExample) | 2008-12-04 |
Family
ID=37667331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538989A Pending JP2008518007A (ja) | 2004-10-29 | 2005-10-19 | 肺感染症の処置のための粒子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8846607B2 (enExample) |
| EP (1) | EP1809252A2 (enExample) |
| JP (1) | JP2008518007A (enExample) |
| CN (1) | CN101090711A (enExample) |
| AU (1) | AU2005334514B2 (enExample) |
| BR (1) | BRPI0517374A (enExample) |
| CA (1) | CA2585859C (enExample) |
| IL (1) | IL182785A0 (enExample) |
| RU (1) | RU2007119721A (enExample) |
| WO (1) | WO2007011396A2 (enExample) |
| ZA (1) | ZA200703452B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2987238T3 (es) | 2008-12-09 | 2024-11-14 | Novavax Inc | Proteínas F del RSV modificadas y métodos de su uso |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| RU2399385C1 (ru) * | 2009-03-10 | 2010-09-20 | Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" | Способ профилактической обработки животных и птиц |
| JP2012524817A (ja) * | 2009-04-24 | 2012-10-18 | シェーリング コーポレイション | 標的粒子サイズを有する、活性医薬を含む凝集体配合物 |
| US20120076838A1 (en) * | 2009-05-27 | 2012-03-29 | Samyang Biopharmaceuticals Corporation | Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| CN102225058A (zh) * | 2011-06-22 | 2011-10-26 | 中国药科大学 | 磷酸奥司他韦吸入粉雾剂及其制备方法 |
| KR20140147891A (ko) * | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 |
| RU2562550C2 (ru) * | 2013-12-19 | 2015-09-10 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) | Способ специфической профилактики туберкулеза |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| WO2018226949A1 (en) | 2017-06-08 | 2018-12-13 | Pai Life Sciences Inc. | Cpzen compositions and uses |
| CN109260180A (zh) * | 2017-07-17 | 2019-01-25 | 北京盈科瑞创新药物研究有限公司 | 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法 |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| CN120227451A (zh) | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| EA202190331A1 (ru) * | 2018-07-24 | 2021-06-17 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки |
| BR112022022243A2 (pt) * | 2020-05-01 | 2022-12-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19. |
| WO2021230340A1 (ja) * | 2020-05-14 | 2021-11-18 | 興和株式会社 | 新規吸入剤 |
| JPWO2022044582A1 (enExample) * | 2020-08-28 | 2022-03-03 | ||
| CA3206024A1 (en) * | 2021-02-01 | 2022-08-04 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid amorphous form |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| CN113907360A (zh) * | 2021-07-30 | 2022-01-11 | 湖南达侑科技有限公司 | 植物甾醇磷脂组合物及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) * | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| IT1228459B (it) * | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| JP2930421B2 (ja) * | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| DE69535897D1 (de) * | 1994-03-07 | 2009-01-22 | Nektar Therapeutics | Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin |
| US5814617A (en) * | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
| DK0752245T3 (da) | 1995-07-05 | 2002-09-09 | Europ Economic Community | Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| ZA9711732B (en) * | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| DE60025019T2 (de) * | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| US6766799B2 (en) * | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| WO2003043586A2 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
| GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| WO2004024213A2 (en) * | 2002-09-12 | 2004-03-25 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Aerosolized capreomycin for inhibition of pulmonary tuberculosis |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| NZ541681A (en) * | 2003-02-10 | 2009-02-28 | Bayer Healthcare Ag | Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts |
-
2005
- 2005-10-19 WO PCT/US2005/037484 patent/WO2007011396A2/en not_active Ceased
- 2005-10-19 CA CA2585859A patent/CA2585859C/en not_active Expired - Fee Related
- 2005-10-19 RU RU2007119721/15A patent/RU2007119721A/ru not_active Application Discontinuation
- 2005-10-19 US US11/720,595 patent/US8846607B2/en not_active Expired - Fee Related
- 2005-10-19 AU AU2005334514A patent/AU2005334514B2/en not_active Ceased
- 2005-10-19 EP EP05858453A patent/EP1809252A2/en not_active Withdrawn
- 2005-10-19 CN CNA2005800449753A patent/CN101090711A/zh active Pending
- 2005-10-19 BR BRPI0517374-4A patent/BRPI0517374A/pt not_active IP Right Cessation
- 2005-10-19 JP JP2007538989A patent/JP2008518007A/ja active Pending
-
2007
- 2007-04-25 IL IL182785A patent/IL182785A0/en unknown
- 2007-04-26 ZA ZA200703452A patent/ZA200703452B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007119721A (ru) | Частицы для лечения легочной инфекции | |
| JP7623854B2 (ja) | 乾燥粉末配合および使用方法 | |
| JP2012503668A5 (enExample) | ||
| CN106456595A (zh) | 用于系统性病症的肥大细胞稳定剂治疗 | |
| JP2011520911A5 (enExample) | ||
| JP2013536845A5 (enExample) | ||
| EP3331522A1 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| JP2011173929A (ja) | 呼吸器官の細菌性疾患の処置 | |
| JP2015515968A5 (enExample) | ||
| CN115768402A (zh) | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 | |
| CN116963738A (zh) | 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺 | |
| JP2007520507A5 (enExample) | ||
| TW200815003A (en) | Treating cystic fibrosis with antibiotics via a swirler delivery | |
| WO2015027848A1 (zh) | 含有帕拉米韦和/或其衍生物制剂的给药方法 | |
| Kaur | Pulmonary drug delivery system: Newer patents | |
| Chaudhary et al. | Recent updates in inhalable drug delivery system against various pulmonary diseases: challenges and future perspectives | |
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| Tamboli et al. | Exploring the frontier of inhalation therapy: a review of dry powder inhalers for precision management of inflammatory lung diseases | |
| JP2022527054A5 (enExample) | ||
| JP2023521898A (ja) | カテキン含有組成物及び使用 | |
| Wang et al. | Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles | |
| Eedara et al. | Pulmonary drug delivery | |
| Dhahir et al. | Dry powder inhalers: main characteristics, classifications and novel drug delivery systems review | |
| WO2023141278A3 (en) | Composite particle formulations and applications thereof | |
| Kumar et al. | Nanostructure-based pulmonary drug delivery systems for respiratory infections |